Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma.
Ramesh K, Mellon EA, Gurbani SS, Weinberg BD, Schreibmann E, Sheriff SA, Goryawala M, de le Fuente M, Eaton BR, Zhong J, Voloschin AD, Sengupta S, Dunbar EM, Holdhoff M, Barker PB, Maudsley AA, Kleinberg LR, Shim H, Shu HG. Ramesh K, et al. Among authors: dunbar em. Neurooncol Adv. 2022 Jan 27;4(1):vdac006. doi: 10.1093/noajnl/vdac006. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35382436 Free PMC article.
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).
Swinnen LJ, O'Neill A, Imus PH, Gujar S, Schiff D, Kleinberg LR, Advani RH, Dunbar EM, Moore D, Grossman SA. Swinnen LJ, et al. Among authors: dunbar em. Oncotarget. 2017 Nov 6;9(1):766-773. doi: 10.18632/oncotarget.22332. eCollection 2018 Jan 2. Oncotarget. 2017. PMID: 29416652 Free PMC article.
A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma.
Ramesh KK, Huang V, Rosenthal J, Mellon EA, Goryawala M, Barker PB, Gurbani SS, Trivedi AG, Giuffrida AS, Schreibmann E, Han H, de le Fuente M, Dunbar EM, Holdhoff M, Kleinberg LR, Shu HG, Shim H, Weinberg BD. Ramesh KK, et al. Among authors: dunbar em. Tomography. 2023 Feb 6;9(1):362-374. doi: 10.3390/tomography9010029. Tomography. 2023. PMID: 36828381 Free PMC article. Clinical Trial.
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.
Rogers JL, Wall T, Acquaye-Mallory AA, Boris L, Kim Y, Aldape K, Quezado MM, Butman JA, Smirniotopoulos JG, Chaudhry H, Tsien CI, Chittiboina P, Zaghloul K, Aboud O, Avgeropoulos NG, Burton EC, Cachia DM, Dixit KS, Drappatz J, Dunbar EM, Forsyth P, Komlodi-Pasztor E, Mandel J, Ozer BH, Lee EQ, Ranjan S, Lukas RV, Raygada M, Salacz ME, Smith-Cohn MA, Snyder J, Soldatos A, Theeler BJ, Widemann BC, Camphausen KA, Heiss JD, Armstrong TS, Gilbert MR, Penas-Prado M. Rogers JL, et al. Among authors: dunbar em. J Neurooncol. 2024 Apr;167(2):349-359. doi: 10.1007/s11060-024-04613-6. Epub 2024 Mar 1. J Neurooncol. 2024. PMID: 38427131 Free PMC article.
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Brachman DG, Pugh SL, Ashby LS, Thomas TA, Dunbar EM, Narayan S, Robins HI, Bovi JA, Rockhill JK, Won M, Curran WP. Brachman DG, et al. Among authors: dunbar em. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):961-7. doi: 10.1016/j.ijrobp.2014.12.050. Int J Radiat Oncol Biol Phys. 2015. PMID: 25832688 Free PMC article. Clinical Trial.
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Weller M, et al. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28844499 Free article. Clinical Trial.
A broad perspective on evaluating bias in the neuro-oncology workplace.
Kumthekar P, Dunbar EM, Peters KB, Brastianos PK, Porter AB. Kumthekar P, et al. Among authors: dunbar em. Neuro Oncol. 2021 Mar 25;23(3):498-499. doi: 10.1093/neuonc/noaa286. Neuro Oncol. 2021. PMID: 33547796 Free PMC article. No abstract available.
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment.
Mrugala MM, Ostrom QT, Pressley SM, Taylor JW, Thomas AA, Wefel JS, Coven SL, Acquaye AA, Haynes C, Agnihotri S, Lim M, Peters KB, Sulman EP, Salcido JT, Butowski NA, Hervey-Jumper S, Mansouri A, Oliver KR, Porter AB, Nassiri F, Schiff D, Dunbar EM, Hegi ME, Armstrong TS, van den Bent MJ, Chang SM, Zadeh G, Chheda MG. Mrugala MM, et al. Among authors: dunbar em. Neurooncol Adv. 2021 Feb 20;3(1):vdab035. doi: 10.1093/noajnl/vdab035. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34007966 Free PMC article.
72 results